Scienza e Tecnologia
BlueSky Immunotherapies GmbH (Ltd.): Phase 1 clinical trial for delNS HPV 16
The trial's primary endpoint is to evaluate safety and to determine the dosage for the subsequent phase 2. First results obtained in the clinical trial have now confirmed the tolerability of the delNS-based vector delNS/E6E7 after subcutaneous administration. In the course of the study, secondary endpoints such as the removal of the HPV 16 infection and the elimination of already existing tumours and tumour cells will also be assessed.
As tumours suppress the activation of an immune response directed against them, they remain virtually invisible to the body's immune system. Treatment with delNS/E6E7 abolishes this immunosuppression. Hence, the immune system can recognise and fight the tumours.
According to , five percent of all cancers worldwide are induced by human papillomaviruses (HPVs). The number of new cases is around 760,000 per year. In addition, there are millions of cases of precancerous lesions, i.e. tissue changes that might become malignant. Treatment options for the invasive form of this cancer are limited and include surgery and chemoradiation which are ineffective and do not treat the underlying HPV infection. The aim of the innovative immunotherapy developed by BlueSky Immunotherapies is to eliminate these existing HPV infections.
It is important to note that the delNS technology platform can also be used for expressing other tumour antigens and thus has an enormous potential for the treatment of other solid tumours.
explains Thomas Muster , CEO of BlueSky Immunotherapies GmbH (Ltd.).
The high level of interferon induced by the delNS vector activates immunological defence reactions against cancer, which
The focus of BlueSky Immunotherapies GmbH (Ltd.) is on utilising its proprietary platform technologies which activate antiviral and antitumoural reactions. BlueSky's unique mix of expertise and experience is geared to the success of new-generation therapies against cancer and infectious diseases.
BlueSky Immunotherapies GmbH (Ltd.)
1060 Vienna , Mariahilfer Straße 101/1/21
Thomas Muster , CEO www.blueskyvaccines.com
office@blueskyvaccines.com
+43 699 19035288
Isolde M. Bergmann
Isolde.Bergmann@gmail.com
+43 699 12278607